Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10485374 | Value in Health | 2005 | 15 Pages |
Abstract
This probabilistic model-based economic evaluation demonstrates how clinical trial data can be combined and integrated with country-specific information about resource utilization and unit cost to assess the cost-effectiveness of bronchodilators in COPD patients. Quality-adjusted life months did not substantially differ between treatment groups. In terms of exacerbations, tiotropium was associated with maximum expected net benefit for plausible values of the ceiling ratio. In sensitivity analyses, this outcome was most sensitive to changes in exacerbation rates.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jan B. MSc, Maureen P.M.H. PhD, Brigitta U. MD, MPH, J. Mark MB, FR, CPC,